Pilot trial: Renal replacement therapy in patients with acute kidney injury and rhabdomyolysis

Pilot trial: Renal replacement therapy in patients with acute kidney injury and rhabdomyolysis - ReplaceRhabdo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023998

Enrollment

Registered

2021-03-03

Start date

2021-03-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17.0 M62.9

Interventions

Group 1: continuous venovenous hemofiltration (CVVH) Group 2: continuous venovenous hemodialysis with high cutoff filter (CVVHD-HCO) Group 3: continuous venovenous hemodialysis with adsorber (CVVHD-ad

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Informed consent - Acute kidney injury requiring renal replacement therapy (according KDIGO guidelines) - Plasma myoglobin level above 4000 µg

Exclusion criteria

Exclusion criteria: - Refuse to participate - Rejection of renal replacement therapy - Age < 18 years - Contraindication for renal replacement therapy, for example end-stage underlying disease - Preexisting end stage kidney disease (CKD G5)/chronic intermittent hemodialysis - Pregnancy and lactation - Participation in other treatment studies

Design outcomes

Primary

Measure	Time frame
marginal mean of myoglobin clearance	—

Secondary

Measure	Time frame
- Clearance of creatinine, urea, beta-2 microglobulin, Il-6, albumin after 1h, 6h, 12h and 24 hours - Lifetime of extracorporeal circuit (filter lifetime) - 90 day outcome: Composite endpoint of patient dead, persistent loss of renal function requiring dialysis or persistent decline in GFR (Slope >10 ml/min/1.72m2 (CKD-EPI)) - Clinical endpoints: o ICU length of stay (days) o ICU mortality o Hospital mortality o Mortality day 28 o Mortality day 90 - Safety endpoints (Intervention period): o Adverse events: - Hypocalcemia - Metabolic alkalosis - Citrate accumulation - Bleeding, requiring blood transfusion - Heparin induced Thrombocytopenia (HIT) - Catheter malfunction o Severe adverse events: - Treatment-associated life-threatening complication - Dead of any cause during intervention	—

Measure

Time frame

- Clearance of creatinine, urea, beta-2 microglobulin, Il-6, albumin after 1h, 6h, 12h and 24 hours - Lifetime of extracorporeal circuit (filter lifetime) - 90 day outcome: Composite endpoint of patient dead, persistent loss of renal function requiring dialysis or persistent decline in GFR (Slope >10 ml/min/1.72m2 (CKD-EPI)) - Clinical endpoints: o ICU length of stay (days) o ICU mortality o Hospital mortality o Mortality day 28 o Mortality day 90 - Safety endpoints (Intervention period): o Adverse events: - Hypocalcemia - Metabolic alkalosis - Citrate accumulation - Bleeding, requiring blood transfusion - Heparin induced Thrombocytopenia (HIT) - Catheter malfunction o Severe adverse events: - Treatment-associated life-threatening complication - Dead of any cause during intervention

—

Countries

Germany

Contacts

Public ContactLorenz Weidhase

Universitätsklinikum Leipzig AöR Interdisziplinäre Internistische Intensivmedizin Leiter: Prof. Dr. med. Sirak Petros

Lorenz.Weidhase@medizin.uni-leipzig.de0341/9712706

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026